Korro Bio (NASDAQ:KRRO) Given New $100.00 Price Target at HC Wainwright

Korro Bio (NASDAQ:KRRO - Free Report) had its price objective decreased by HC Wainwright from $115.00 to $100.00 in a research report report published on Thursday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Korro Bio's Q4 2026 earnings at ($2.17) EPS and FY2026 earnings at ($8.32) EPS.

A number of other equities research analysts also recently weighed in on KRRO. Royal Bank of Canada dropped their target price on Korro Bio from $105.00 to $95.00 and set an "outperform" rating for the company in a report on Wednesday, March 19th. Oppenheimer assumed coverage on Korro Bio in a research note on Friday, January 10th. They set an "outperform" rating and a $155.00 target price for the company. Cantor Fitzgerald raised Korro Bio to a "strong-buy" rating in a research note on Tuesday, April 29th. Finally, Chardan Capital assumed coverage on Korro Bio in a research note on Wednesday, April 16th. They set a "buy" rating and a $25.00 target price for the company. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Korro Bio has a consensus rating of "Buy" and a consensus target price of $104.63.

Korro Bio Price Performance

KRRO stock traded down $0.36 during midday trading on Thursday, reaching $15.62. 88,153 shares of the company were exchanged, compared to its average volume of 91,051. The business has a 50-day moving average price of $17.66 and a two-hundred day moving average price of $33.72. Korro Bio has a one year low of $11.13 and a one year high of $98.00. The firm has a market capitalization of $146.69 million, a price-to-earnings ratio of -1.65 and a beta of 2.66.

Korro Bio (NASDAQ:KRRO - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($2.49) EPS for the quarter, topping analysts' consensus estimates of ($2.60) by $0.11. The company had revenue of $2.55 million for the quarter, compared to the consensus estimate of $0.13 million. As a group, analysts anticipate that Korro Bio will post -9.52 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Korro Bio

Several institutional investors have recently added to or reduced their stakes in KRRO. KLP Kapitalforvaltning AS acquired a new position in Korro Bio in the fourth quarter valued at approximately $53,000. AlphaQuest LLC raised its position in shares of Korro Bio by 23.2% during the fourth quarter. AlphaQuest LLC now owns 2,189 shares of the company's stock worth $83,000 after purchasing an additional 412 shares during the period. Wells Fargo & Company MN raised its position in shares of Korro Bio by 32.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,392 shares of the company's stock worth $129,000 after purchasing an additional 831 shares during the period. Deutsche Bank AG raised its position in shares of Korro Bio by 29.4% during the fourth quarter. Deutsche Bank AG now owns 4,110 shares of the company's stock worth $156,000 after purchasing an additional 935 shares during the period. Finally, Legal & General Group Plc lifted its position in shares of Korro Bio by 664.1% during the fourth quarter. Legal & General Group Plc now owns 4,325 shares of the company's stock valued at $165,000 after purchasing an additional 3,759 shares in the last quarter. 13.18% of the stock is owned by institutional investors and hedge funds.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).